	US 12,104,209 B2
	Non-invasive diagnostic of non-alcoholic steatohepatitis
Raphaël Darteil, Villeurbanne (FR); Geneviève Cordonnier, Templemars (FR); John Brozek, Saint-Amand-les-Eaux (FR); Emilie Praca, Lille (FR); and Fouad Ben Sudrik, Lille (FR)
Assigned to GENFIT, Loos (FR)
Appl. No. 16/089,835
Filed by Genfit, Loos (FR)
PCT Filed Mar. 30, 2017, PCT No. PCT/EP2017/057633 § 371(c)(1), (2) Date Sep. 28, 2018, PCT Pub. No. WO2017/167934, PCT Pub. Date Oct. 5, 2017.
Claims priority of application No. 16163048 (EP), filed on Mar. 30, 2016.
Prior Publication US 2019/0352715 A1, Nov. 21, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); A61K 31/216 (2006.01); C12Q 1/54 (2006.01); C12Q 1/6827 (2018.01); G06F 17/18 (2006.01); G16B 5/20 (2019.01); G16B 25/00 (2019.01); G16B 40/10 (2019.01); G16H 50/30 (2018.01)

CPC C12Q 1/6883 (2013.01) [A61K 31/216 (2013.01); C12Q 1/54 (2013.01); C12Q 1/6827 (2013.01); G06F 17/18 (2013.01); G16B 5/20 (2019.02); G16B 25/00 (2019.02); G16B 40/10 (2019.02); G16H 50/30 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/085 (2013.01)]

11 Claims

1. A method for diagnosing and treating non-alcoholic steatohepatitis (NASH) the method comprising:

(i) measuring levels of blood, serum or plasma circulating hsa-miR-34, YKL-40, and at least one other blood, serum or plasma circulating marker of liver damage of a subject and combining the levels of hsa-miR-34, YKL-40, and the other blood, serum or plasm circulating marker(s) of liver damage through a mathematical algorithm to obtain a NASH score;

(ii) comparing said NASH score with a threshold value to diagnose moderate and severe NASH or low, moderate, and high NASH activity in the subject; and

(iii) administering to the subject diagnosed in step (ii) as having severe NASH, low NASH activity, moderate NASH activity, or high NASH activity an effective amount of an anti-NASH compound.